
Darolutamide Plus ADT Cuts Risk of Progression or Death in mHSPC
The Phase III ARANOTE trial results reveal that darolutamide combined with androgen deprivation therapy (ADT) significantly decreased the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) (HR…











